Muscle Spasm - Pipeline Review, H1 2015

Date: April 15, 2015
Pages: 42
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: M9F72FA971CEN
Leaflet:

Download PDF Leaflet

Muscle Spasm - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Muscle Spasm - Pipeline Review, H1 2015’, provides an overview of the Muscle Spasm’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Muscle Spasm, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Muscle Spasm and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Muscle Spasm
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Muscle Spasm and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Muscle Spasm products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Muscle Spasm pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Muscle Spasm
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Muscle Spasm pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Muscle Spasm Overview
Therapeutics Development
Pipeline Products for Muscle Spasm - Overview
Pipeline Products for Muscle Spasm - Comparative Analysis
Muscle Spasm - Therapeutics under Development by Companies
Muscle Spasm - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Muscle Spasm - Products under Development by Companies
Muscle Spasm - Companies Involved in Therapeutics Development
Eisai Co., Ltd.
Omeros Corporation
Revance Therapeutics, Inc.
Sanochemia Pharmazeutika AG
Muscle Spasm - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(diclofenac sodium + eperisone) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(ketoprofen + nifedipine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize TRPA1 and TRPV1 for Neuromuscular Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NVP-1102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RT-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tolperisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Muscle Spasm - Recent Pipeline Updates
Muscle Spasm - Dormant Projects
Muscle Spasm - Product Development Milestones
Featured News & Press Releases
Nov 12, 2013: Sanochemia Receives First Patent For Japan
Nov 23, 2012: Sanochemia Receives US Notice Of Allowance For Manufacture Of Tolperisone
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Muscle Spasm, H1 2015
Number of Products under Development for Muscle Spasm - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Muscle Spasm - Pipeline by Eisai Co., Ltd., H1 2015
Muscle Spasm - Pipeline by Omeros Corporation, H1 2015
Muscle Spasm - Pipeline by Revance Therapeutics, Inc., H1 2015
Muscle Spasm - Pipeline by Sanochemia Pharmazeutika AG, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Muscle Spasm Therapeutics - Recent Pipeline Updates, H1 2015
Muscle Spasm - Dormant Projects, H1 2015

LIST OF FIGURES

Number of Products under Development for Muscle Spasm, H1 2015
Number of Products under Development for Muscle Spasm - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Skip to top


Muscle Spasm - Pipeline Review, H2 2014 US$ 1,600.00 Dec, 2014 · 35 pages
Muscle Atrophy - Pipeline Review, H1 2015 US$ 1,600.00 Feb, 2015 · 42 pages
Muscle Spasticity - Pipeline Review, H1 2015 US$ 1,600.00 Jan, 2015 · 49 pages
Muscle Atrophy - Pipeline Review, H2 2015 US$ 1,600.00 Sep, 2015 · 41 pages
Muscle Spasticity - Pipeline Review, H2 2015 US$ 1,600.00 Aug, 2015 · 51 pages

Ask Your Question

Muscle Spasm - Pipeline Review, H1 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: